Showing 1901-1910 of 5771 results for "".
- Ophthalmic World Leaders Announces Development and Networking Program for Executives Seeking Corporate Board Positionshttps://modernod.com/news/ophthalmic-world-leaders-announces-development-and-networking-program-for-executives-seeking-corporate-board-positions/2479130/Ophthalmic World Leaders (OWL) has announced its inaugural “Get-On-Board with OWL” program. Primarily aimed at executive-level women and underrepresented communities, this new offering will help attendees develop the skills and connections required to secure board positions in a rapid
- Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/aerie-pharmaceuticals-announces-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479128/Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases, announced it will participate and have poster
- Novaliq Announces More Than Half of Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2https://modernod.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/Novaliq announced today that the second Phase 3 clinical trial evaluating CyclASol to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the second half of 2021. The Phase 3 program for CyclASol
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2021-arvo-annual-meeting/2479123/Allegro Ophthalmics announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held virtually May 1-7, 2021. “It’s e
- Glaukos Announces Global Licensing Agreement Amendment with Intratus to Include the Treatment of Presbyopiahttps://modernod.com/news/glaukos-announces-global-licensing-agreement-amendment-with-intratus-to-include-the-treatment-of-presbyopia/2479115/Glaukos announced that it has entered into an amended licensing agreement with Intratus under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, noninvasive drug delivery platform (the Eyelid Drug Delivery Platform
- ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at ARVO 2021https://modernod.com/news/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-extension-trial-data-at-arvo-2021/2479108/ProQR Therapeutics announced a virtual oral presentation of data from the company’s phase 1/2 InSight extension trial of sepofarsen and live Q&A session at the Association for Research in Vision and Ophthalmology (ARVO) held May 1-7, 2021. This is an encore presentation of the In
- Nidek Marks 50th Anniversary and Renews Logohttps://modernod.com/news/nidek-marks-50th-anniversary-and-renews-logo/2479104/Nidek will mark its 50th anniversary on August 8th, 2021. To mark this milestone, the company has renewed its logo. While this symbol con
- Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479093/Palatin Technologies announced two presentations of the company’s melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021. The
- Bausch Health Announces Vyzulta is Now Approved In Brazilhttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-brazil/2479084/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária). Vyzulta is indicated for the reduction of IOP in pa
- ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-in-nature-medicine-for-sepofarsen-in-leber-congenital-amaurosis-10/2479077/ProQR Therapeutics announced the publication in the scientific journal